TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05306067

Intervention type: DIAGNOSTIC_TEST
Intervention: LDH-based malaria rapid diagnostic test
Description: Malaria testing using an LDH-based malaria rapid diagnostic test will be added to standard routine testing of suspected cases at health facilities

Intervention type: DIAGNOSTIC_TEST
Intervention: Malaria rapid diagnostic test
Description: All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Malaria rapid diagnostic test
Description: All pregnant women attending their first routine antenatal visit will be tested for malaria using routine malaria rapid diagnostic tests
Study: NCT06168643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: Physical therapy interventions will include core stability exercises which will be demonstrated and will be checked if they are being performed correctly. The exercises guided shall be performed 3 times daily and logbook will be provided to keep the record of exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability with pregnancy support belt
Description: Participants will receive same information and exercises as those in Group A. they will also receive pregnancy support belt. The logbook will be provided to keep the record of hours the belt has been worn along with exercise record.
Study: NCT05101187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olorofim
Description: Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmBisome®
Description: Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
Study: NCT05132231

Intervention type: BIOLOGICAL
Intervention: Brodalumab
Description: Brodalumab
Study: NCT06700720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 140 mg will be administered subcutaneously every 2 weeks.
Study: NCT06700434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bleaching treatment
Description: After the lip retractor (OptraGate, Ivoclar Vivadent, Schaan, Liechtenstein) was placed, the gingival barrier protection (Biowhiten, Biodent Ltd., İstanbul, Turkey) included in the products was applied to the upper and lower arches from premolar to premolar at the beginning of each session and removed after each treatment. The bleaching gels were applied according to the manufacturer and removed after the recommended period with a disposable surgical saliva ejector, cleaned with gauze and washed with air-water spray. Two bleaching sessions were performed at a 1-week interval. Participants were advised to maintain regular oral hygiene by brushing with toothpaste that does not contain desensitizing or whitening ingredients.~HP18 is applied in 5 applications of 10 minutes per session. HP25 is applied in 3 applications of 15 minutes per session. HP40 is applied in 3 applications of 15 minutes per session.
Study: NCT05132231

Intervention type: BIOLOGICAL
Intervention: Matched cohort
Description: Matched cohort
Study: NCT06700434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bleaching treatment
Description: After the lip retractor (OptraGate, Ivoclar Vivadent, Schaan, Liechtenstein) was placed, the gingival barrier protection (Biowhiten, Biodent Ltd., İstanbul, Turkey) included in the products was applied to the upper and lower arches from premolar to premolar at the beginning of each session and removed after each treatment. The bleaching gels were applied according to the manufacturer and removed after the recommended period with a disposable surgical saliva ejector, cleaned with gauze and washed with air-water spray. Two bleaching sessions were performed at a 1-week interval. Participants were advised to maintain regular oral hygiene by brushing with toothpaste that does not contain desensitizing or whitening ingredients.~HP18 is applied in 5 applications of 10 minutes per session. HP25 is applied in 3 applications of 15 minutes per session. HP40 is applied in 3 applications of 15 minutes per session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bleaching treatment
Description: After the lip retractor (OptraGate, Ivoclar Vivadent, Schaan, Liechtenstein) was placed, the gingival barrier protection (Biowhiten, Biodent Ltd., İstanbul, Turkey) included in the products was applied to the upper and lower arches from premolar to premolar at the beginning of each session and removed after each treatment. The bleaching gels were applied according to the manufacturer and removed after the recommended period with a disposable surgical saliva ejector, cleaned with gauze and washed with air-water spray. Two bleaching sessions were performed at a 1-week interval. Participants were advised to maintain regular oral hygiene by brushing with toothpaste that does not contain desensitizing or whitening ingredients.~HP18 is applied in 5 applications of 10 minutes per session. HP25 is applied in 3 applications of 15 minutes per session. HP40 is applied in 3 applications of 15 minutes per session.
Study: NCT06700512

Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing Aid Signia Pure C&G 7IX
Description: Receiver in Canal (RIC) hearing aid, M Receiver

Intervention type: DEVICE
Group type: OTHER
Intervention: Own Hearing Aid
Description: subjects' own hearing aids, any brand, any model
Study: NCT06701175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block
Description: anterolateral geniculate nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal Anesthesia
Description: portal anesthesia
Study: NCT06701136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine
Description: In Study A, Cycle 1 (D1-D10): Participants will take Sudapyridine (WX-081) 300 mg once daily after breakfast. Cycle 2 (D11-D14): Participants will take Sudapyridine 300 mg once daily after breakfast with itraconazole 200 mg daily; an additional itraconazole dose (200 mg) will be given after dinner on D11. In Study B, Cycle 1 (D1): Participants will take Sudapyridine 450 mg as a single dose after breakfast. Cycle 2 (D22): Participants will take Sudapyridine 450 mg with rifampin 600 mg daily (D15-D27). In Study C, Cycle 1 (D1): Sudapyridine 450 mg will be given fasting; Cycle 2 (D15): after a high-fat breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine
Description: In Study A, Cycle 1 (D1-D10): Participants will take Sudapyridine (WX-081) 300 mg once daily after breakfast. Cycle 2 (D11-D14): Participants will take Sudapyridine 300 mg once daily after breakfast with itraconazole 200 mg daily; an additional itraconazole dose (200 mg) will be given after dinner on D11. In Study B, Cycle 1 (D1): Participants will take Sudapyridine 450 mg as a single dose after breakfast. Cycle 2 (D22): Participants will take Sudapyridine 450 mg with rifampin 600 mg daily (D15-D27). In Study C, Cycle 1 (D1): Sudapyridine 450 mg will be given fasting; Cycle 2 (D15): after a high-fat breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: In Study A: Participants will receive itraconazole capsules at 200 mg orally once daily after breakfast during Cycle 2 (D11-D14). An additional dose of itraconazole (200 mg) will be administered after dinner on D11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: In Study B: Participants will receive rifampin capsules at 600 mg orally once daily under fasting conditions during Cycle 2 (D15-D27).
Study: NCT06701097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation training
Description: Man is a social being and therefore interacts with his environment. In the process of interaction, they can transfer their feelings, thoughts, and information. However, the interaction process may not always continue smoothly. People's inability to express their emotions appropriately today negatively affects communication. The reason why people cannot express their emotions may be the high level of alexithymia. The concept of alexithymia means having difficulty in recognizing, expressing, and naming emotions. High levels of alexithymia in students, who are future healthcare professionals, can negatively affect themselves, other healthcare professionals and the patients they care for; it can cause burnout in healthcare professionals, decrease the quality of care they provide and cause them to experience interpersonal communication conflicts.
Study: NCT06704061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A 12-week online yoga course designed to treat pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: A 12-week behavioral therapy course designed to treat pain.
Study: NCT06703762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: He-Ne low level laser (LLL)
Description: Patients in the experimental group will receive treatment with LLLT. The ulcer bed will be irradiated locally with red light (660 nm). The ulcer size and its depth will be used as the basis to calculate the duration of exposure needed to deliver 3-10 J/cm² for 15 to 20 minutes. The application will take place in 3 sessions per week for 4 weeks. Each patient will be asked to lie in a supine position with the ulcer easily exposed to the laser beam, and they will be instructed to wear laser glasses and avoid looking directly at the beam until the end of the session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional traditional treatment
Description: All patients in both the groups will receive the required, conventional treatments of diabetic wound care, including dressing, antibiotics, controlling diabetes, cholesterol, and blood pressure along with aggressive drug treatment and wound debridement when needed.
Study: NCT05060419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem- FL058
Description: Meropenem-FL058(Meropenem 1000mg plus FL058 1000mg)q8h~Meropenem-FL058(Meropenem 2000mg plus FL058 1000mg)q8h
Study: NCT06210178

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: MRI scans including abdominal 4D Flow MRI.
Study: NCT05060419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin -tazobactam
Description: Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g)q8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 180min
Study: NCT05094947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent catheterization
Description: clean intermittent catheterization with catheter Nelaton

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trial without catheter
Description: catheter Foley

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha-blockers
Description: tamsulosin, alfuzosin, doxazosin, silodosin
Study: NCT05060419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 30min
Study: NCT05094947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-blockers
Description: tamsulosin, alfuzosin, doxazosin, silodosin
Study: NCT06248021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Footprint Awareness Program
Description: The program was conducted for four weeks, one day each week, for 40 minutes. Each week, a different topic was addressed such as waste evaluation, water and energy usage, food consumption, and transportation. The program was created in line with expert opinions and literature. The sessions were based on the principles of the Social Cognitive Learning Theory, developed by Bandura, which includes mutual determinism, symbolization, anticipatory capacity, vicarious learning, self-regulation capacity, and self-judgment capacity. During each session, various techniques such as animation, drawing, storytelling, memory cards, and games were employed. To ensure the program's content was appropriate for children's development, the opinions of two experts from the child development department of the university were obtained.
Study: NCT06108050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP898
Description: Investigational drug monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP898
Description: Investigational drug monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP898
Description: Investigational drug monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Approved anti-PD1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Approved anti-PD1 antibody
Study: NCT05092776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for subcutaneous Injection), 2 mL in the 4 mL-glass vial. The placebo will contain no active pharmaceutical ingredients.
Study: NCT06080438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: 15 units of botulinum toxin administered one time to the eye via eye drops
Study: NCT05165524

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QS Nd:YAG laser
Description: Patients will be treated with Quality-switched (QS) Neodymium-doped yttrium aluminum garnet (Nd:YAG) laser (MedLite® C6) operating at a wavelength of 1064 nm, fluence range from 2.1 J/cm2 to 8.1 J/cm2 with a 4-6mm spot size.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple cream
Description: Patients will be treated with a triple brightening cream (Pigmanorm®), applied daily, three times per week for 12 weeks on the lesion. Interruption for 4 days will be adopted in case of irritation/redness. 50+ sun protection cream will be used as well during the treatment period.
Study: NCT05374174

Intervention type: DIAGNOSTIC_TEST
Intervention: Tardieu Scale for Spasticity
Description: The clinician will rotate the elbow joint at various speeds while the participant sits relaxed.
Study: NCT06573515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone power therapy
Description: female patients will receive high-tone power therapy using a device (HiTop 191 Medizintechnik, Rimbach, Germany) duration 30 minutes at 2 sessions per week for 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interferential current therapy
Description: female patients will receive interferential current therapy using Enraf-Nonius (ENDOMED 484, Germany)The electrode pairs will placed at a distance of at least 2.5 cm from each other. The utilized parameters will have a base frequency of 4,000 Hz, a modulation frequency range of 10 Hz-20 Hz, spectrum mode triangular, and slope 1/1 in a quadripolar manner with a beat frequency of 80 Hz. duration of treatment session 20 minutes 2 sessions per week for 6 weeks
Study: NCT05265247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg Delayed-Release Capsules
Description: Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg Delayed-Release Capsules
Description: Esomeprazole 20 mg delayed-release capsules will be given as one capsule once daily as oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)
Description: Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg Delayed-Release Capsules (Nexium 24HR)
Description: Esomeprazole 20 mg delayed-release capsules (Nexium 24HR) will be given as one capsule once daily as oral administration.
Study: NCT05583474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-1085EL
Description: one drop for each eye, once per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.005% Latanoprost
Description: one drop for each eye, once per day
Study: NCT06020495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP
Description: Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard hyponatremia treatment
Description: Standard hyponatremia treatment alone :~Presence of neurological symptoms :~sodium chloride 3% 150ml for 20 min Absence of neurological symptoms : Hyper or isotonic fluid but never hypotonic
Study: NCT05815693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based stress reduction (MBSR) and cognitive behavioral therapy (CBT)
Description: Patients with long-term consequences of COVID-19 (Chronic pain, anxiety, depression or insomnia) enrolled and randomly assigned to receive MBSR (n = 63), or usual care (n = 62). MBSR (training in mindfulness meditation and yoga) were delivered in 12 months with 2-hour groups each 2 months. Usual care included anything care participants received such as drug therapy.
Study: NCT06573515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: female patients will receive conventional physical therapy modalities in the form of (ultrasound, massage, stretching, and strengthening exercises) 2 sessions per week for 6 weeks
Study: NCT02230657

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Same day discharge

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Next day discharge
Study: NCT04194671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: In experimental group, patients receive standard treatment and allogeneic human umbilical cord derived-mesenchymal stem cells (MSCs) is administered via intravenous infusion on day 0 and day 7

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: In placebo control group, patients receive standard treatment and saline is administered via intravenous infusion on day 0 and day 7
Study: NCT05033158

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling before and after COVID-19 vaccination
Study: NCT05453305

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Traditional venipuncture, on the stretcher.
Description: The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial assessment of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child pain and stress using FLACC and Groningen scale and will record it. Next, the companion will place the child on the stretcher in supine position with the limb to be punctured in decline. During the technique, the companion will be present, being able to participate by establishing links of consolation or distraction, as is usually done in the hospital. Simultaneously, a professional from the service will be in charge of holding the chosen extremity, as well as the opposite one. The responsible nurse will perform the venipuncture and/or collecting samples. The observer will assess child's pain and stress and caregiver's STAI during the intervention with the same scales.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention group: DAK method venipuncture, simulating a hug
Description: The companion will be given the State/Trait Anxiety Questionnaire(STAI) for the initial evaluation of the companion's anxiety and will be asked to recall their perceived emotions during the venipuncture. The observer will assess child's pain and stress using the FLACC and Groningen scale and record it. Subsequently, the caregiver will sit in a chair placing the child on top in front of him, with one leg on each side and the arms resting on the shoulders of the companion. The patient's head will rest on the adult's shoulder, contralateral to the limb to be punctured. Simultaneously, the responsible adult patient will hold the simulating a hug. A professional will take care of immobilizing the chosen limb. The responsible nurse performed the venipuncture and collecting samples. The observer will assess the child's pain and stress during the intervention, and will deliver the STAI to the caregiver, to be completed with their perceived sensations during the technique.
Study: NCT05233072

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Arm 'Fracture':1 blood sample at D0, D1, D3, D7 and D30 Arm 'Control': 1 blood sample at D0
Study: NCT06703762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional traditional treatment
Description: All patients in both the groups will receive the required, conventional treatments of diabetic wound care, including dressing, antibiotics, controlling diabetes, cholesterol, and blood pressure along with aggressive drug treatment and wound debridement when needed.
Study: NCT06702735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rainbow tool
Description: The Rainbow tool visualizes perception based on lung function measurements and VAS scores.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rainbow tool
Description: The Rainbow tool visualizes perception based on lung function measurements and VAS scores.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Feedback sessions with health care professional based on the Rainbow tool.
Study: NCT06702384

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: Baseline biopsy and biological specimens

Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy
Description: Baseline biopsy and biological specimens
Study: NCT06703125

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Eyelink Portable Duo
Description: Eye-tracking data will be collected using a commercially-available remote eye-tracking system (Eyelink Portable Duo). Eye movements and pupil diameter will be collected while participants view a series of developmentally appropriate pictures and movies. The eye-tracker consists of two cameras; one that monitors eye movements and a second scene camera that monitors head movements, which permits eye tracking to take place without any equipment touching the child. Children will be asked to sit in highchair or on their the lap of the caregiver and will face a computer monitor. After a sticker is applied to the forehead of the child and brief eye-movement calibration completed, next visual stimuli (i.e., pictures and videos) will be presented on a laptop computer monitor that is placed at approximately 60-80cm from the child. The eye tracking portion of the visit will last approximately 15 minutes or until the child is no longer able to attend to pictures/videos.